|Bid||88.88 x 900|
|Ask||88.92 x 900|
|Day's Range||88.66 - 90.92|
|52 Week Range||62.48 - 110.37|
|Beta (5Y Monthly)||1.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||106.40|
Novartis earnings beat third-quarter views while sales came in light. Full-year revenue guidance was in line for the Swiss drug giant. Shares fell.
Eli Lilly early Tuesday posted third-quarter earnings and sales that missed Wall Street expectations and said that one of its Covid-19 treatments failed in clinical trials; LLY stock fell.
MONTREAL, Oct. 26, 2020 /CNW/ - Incyte (Nasdaq: INCY) today announced that Health Canada has accepted its New Drug Submission (NDS) for pemigatinib, a selective fibroblast growth factor receptor (FGFR) inhibitor, as a treatment for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement.